The online version of this article (doi:10.1186/1758-5996-6-42) contains supplementary material, which is available to authorized users.
Flávio Reis and Edite Teixeira de Lemos contributed equally to this work.
The authors declare that they have no competing interest.
CM, FT, RF, FR and ETL conceived and designed the study protocol. CM, HV, PR-S, RF, FR and ETL participated in the animal handling and biochemical laboratory assays. HV and PR-S coordinated the histopathological and gene expression studies, respectively. CM, HV, JO, FR and ETL analyzed the data. CM, JO, RF, FR and ETL prepared the manuscript. FR and ETL equally contributed to the work and are co-last authors and co-responsible for the work and manuscript. All authors read and approved the final manuscript.
The purpose of this study was to investigate some of the possible mechanisms underlying the protective effects of a dipeptidyl peptidase IV (DPP-IV) inhibitor, sitagliptin, on pancreatic tissue in an animal model of type 2 diabetes mellitus (T2DM), the Zucker Diabetic Fatty (ZDF) rat, focusing on glycaemic, insulinic and lipidic profiles, as well as, on apoptosis, inflammation, angiogenesis and proliferation mediators.
Male obese diabetic ZDF (fa/fa) rats, aged 20 weeks, were treated with sitagliptin (10 mg/kg bw/day) during 6 weeks and compared to untreated diabetic and lean control littermates. Metabolic data was evaluated at the beginning and at the end of the treatment, including glycaemia, HbA1c, insulinaemia, HOMA-beta and TGs. Endocrine and exocrine pancreas lesions were assessed semiquantitatively by histopathological methods. Pancreas gene (mRNA) and protein expression of mediators of apoptotic machinery, inflammation and angiogenesis/proliferation (Bax, Bcl2, IL-1β, VEGF, PCNA and TRIB3) were analyzed by RT-qPCR and/or by immunohistochemistry.
Sitagliptin treatment for 6 weeks (between 20 and 26 week-old) was able to significantly (p < 0.001) ameliorate all the metabolic parameters, by preventing the increase in blood glucose and in serum TGs contents (16.54% and 37.63%, respectively, vs untreated), as well as, by preventing the decrease in serum insulin levels and in the functional beta cells capacity accessed via HOMA-beta index (156.28% and 191.74%, respectively, vs untreated). Sitagliptin-treated diabetic rats presented a reduced pancreas Bax/Bcl2 ratio, suggestive of an antiapoptotic effect; in addition, sitagliptin was able to completely reduce (p < 0.001) the pancreas overexpression of IL-1β and TRIB3 found in the untreated diabetic animals; and promoted a significant (p < 0.001) overexpression of VEGF and PCNA.
In this animal model of obese T2DM (the ZDF rat), sitagliptin prevented β-cell dysfunction and evolution of pancreatic damage. The protective effects afforded by this DPP-IV inhibitor may derive from improvement of the metabolic profile (viewed by the amelioration of glucose and TGs levels and of insulin resistance) and from cytoprotective properties, such as antiapoptotic, anti-inflammatory, pro-angiogenic and pro-proliferative.
Authors’ original file for figure 113098_2014_414_MOESM1_ESM.tif
Authors’ original file for figure 213098_2014_414_MOESM2_ESM.tif
Authors’ original file for figure 313098_2014_414_MOESM3_ESM.tif
Authors’ original file for figure 413098_2014_414_MOESM4_ESM.tif
Authors’ original file for figure 513098_2014_414_MOESM5_ESM.tif
World Health Organization: Diabetes Fact sheet N°312. Updated March 2013; http://www.who.int/mediacentre/factsheets/fs312/en/
Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. 1999, Geneva: World Health Organization, (WHO/NCD/NCS/99.2). http://www.staff.ncl.ac.uk/philip.home/who_dmg.pdf
Virally M, Blicklé JF, Girard J, Halimi S, Simon D, Guillausseau PJ: Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives. Diabet Med. 2007, 33: 231-244.
Poitout V, Robertson RP, Minireview: Secondary beta-cell failure in type 2 diabetes - a convergence of glucotoxicity and lipotoxicity. Endocrinology. 2002, 143 (2): 339-342. PubMed
Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ: Both subcutaneously and intravenously administered glucagon-like peptide-1 are rapidly degraded from the NH2-terminus in type II diabetic patients and healthy subjects. Diabetes. 1995, 44 (9): 1126-1131. 10.2337/diab.44.9.1126. CrossRefPubMed
Martín-Cordero L, García JJ, Hinchado MD, Ortega E: The interleukin-6 and noradrenaline mediated inflammation-stress feedback mechanism is dysregulated in metabolic syndrome: effect of exercise. Cardiovasc Diabetol. 2011, 20: 10-42.
Huang CJ, Lin CY, Haataja L, Gurlo T, Butler AE, Rizza RA, Butler PC: High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes. 2007, 56: 2016-2027. 10.2337/db07-0197. CrossRefPubMed
Ferreira L, Teixeira-de-Lemos E, Pinto F, Parada B, Mega C, Vala H, Pinto R, Garrido P, Sereno J, Fernandes R, Santos P, Velada I, Melo A, Nunes S, Teixeira F, Reis F: Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm. 2010, 2010: 592760- PubMedCentralPubMed
Teixeira de Lemos E, Reis F, Baptista S, Pinto R, Sepodes B, Vala H, Rocha-Pereira P, Correia da Silva G, Teixeira N, Silva AS, Carvalho L, Teixeira F: Exercise training decreases proinflammatory profile in Zucker diabetic (type 2) fatty rats. Nutrition. 2009, 25 (3): 330-339. 10.1016/j.nut.2008.08.014. CrossRefPubMed
Aleksey V, Matveyenko AV, Dry S, Cox HI, Moshtaghian A, Gurlo T, Galasso R, Butler AE, Butler PC: Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes interactions with metformin. Diabetes. 2009, 58 (7): 1604-1615. 10.2337/db09-0058. CrossRef
Maiztegui B, Borelli MI, Madrid VG, Del Zotto H, Raschia MA, Francini F, Massa ML, Flores LE, Rebolledo OR, Gagliardino JJ: Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats. Clin Sci. 2011, 120: 73-80. 10.1042/CS20100372. CrossRefPubMed
Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, Feng Y, Zhu L, Li C, Howard AD, Moller DE, Thornberry NA, Zhang BB: Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes. 2006, 55 (6): 1695-1704. 10.2337/db05-1602. CrossRefPubMed
Gonçalves A, Leal E, Paiva A, Teixeira Lemos E, Teixeira F, Ribeiro CF, Reis F, Ambrósio AF, Fernandes R: Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model. Diabetes Obes Metab. 2012, 14 (5): 454-463. 10.1111/j.1463-1326.2011.01548.x. CrossRefPubMed
Darnell D, Davis T, GilFillan C, Karrasch J, Lowy A, Bantwal G, Basavanagowdappa H, Chandalia H, Kumar H, Modi K, Paturi V, Seshaiah V, Sethi B, Shah S, Yajnik C, De Mattia G, Ghirlanda G, Hussein Z, Natkunam SK, Ramanathan GR, Sarvar MM, Tan HS, Benatar J, Leikis R, Scott R, Arciszewska M, Babol I, Gabryel A, Krzyczkowska-Bokwa E, Kula M: Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008, 10 (10): 959-969. 10.1111/j.1463-1326.2007.00839.x. CrossRef
Gallwitz B: Extra-pancreatic effects of incretin-based therapies. 2014, [Epub ahead of print]
Dinarello CA, Donath MY, Mandrup-Poulsen T: Role of IL-1beta in type 2 diabetes. Curr Opin Endocrinol Diabetes Obes. 2010, 17 (4): 314-321. PubMed
Satoh-Asahara N, Sasaki Y, Wada H, Tochiya M, Iguchi A, Nakagawachi R, Odori S, Kono S, Hasegawa K, Shimatsu A: A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism. 2013, 62 (3): 347-351. 10.1016/j.metabol.2012.09.004. CrossRefPubMed
Derosa G, Carbone A, D'Angelo A, Querci F, Fogari E, Cicero AF, Maffioli P: Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin. Intern Med. 2013, 52 (19): 2179-2187. 10.2169/internalmedicine.52.8175. CrossRefPubMed
Duvillié B, Currie C, Chrones T, Bucchini D, Jami J, Joshi RL, Hill DJ: Increased islet cell proliferation, decreased apoptosis, and greater vascularization leading to beta-cell hyperplasia in mutant mice lacking insulin. Endocrinology. 2002, 143 (4): 1530-1537. PubMed
Shimoda M, Kanda Y, Hamamoto S, Tawaramoto K, Hashiramoto M, Matsuki M, Kaku K: The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia. 2011, 54 (5): 1098-1108. 10.1007/s00125-011-2069-9. PubMedCentralCrossRefPubMed
Hamamoto S, Kanda Y, Shimoda M, Tatsumi F, Kohara K, Tawaramoto K, Hashiramoto M, Kaku K: Vildagliptin preserves the mass and function of pancreatic β cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetes Obes Metab. 2013, 15 (2): 153-163. 10.1111/dom.12005. PubMedCentralCrossRefPubMed
Prudente S, Scarpelli D, Chandalia M, Zhang YY, Morini E, Del Guerra S, Perticone F, Li R, Powers C, Andreozzi F, Marchetti P, Dallapiccola B, Abate N, Doria A, Sesti G, Trischitta V: The TRIB3 Q84R Polymorphism and Risk of Early-Onset Type 2 Diabetes. J Clin Endocrinol Metab. 2009, 94 (1): 190-196. 10.1210/jc.2008-1365. PubMedCentralCrossRefPubMed
Liu J, Wu X, Franklin JL, Messina JL, Hill HS, Moellering DR, Walton RG, Martin M, Garvey WT: Mammalian Tribbles homolog 3 impairs insulin action in skeletal muscle: role in glucose-induced insulin resistance. Am J Physiol Endocrinol Metab. 2010, 298: E565-E576. 10.1152/ajpendo.00467.2009. PubMedCentralCrossRefPubMed
Prudente S, Hribal ML, Flex E, Turchi F, Morini E, De Cosmo S, Bacci S, Tassi V, Cardellini M, Lauro R, Sesti G, Dallapiccola B, Trischitta V: The functional Q84R polymorphism of mammalian Tribbles homolog TRB3 is associated with insulin resistance and related cardiovascular risk in Caucasians from Italy. Diabetes. 2005, 54: 2807-2811. 10.2337/diabetes.54.9.2807. CrossRefPubMed
- Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties
Edite Teixeira de Lemos
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II